KRRO — Korro Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1703647 ·
Last close
$9.51
Market Cap
$140.04M
52W High
$55.89
52W Low
$5.20
ADV30
158,634
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -20,110,000 | -18,916,000 | 163,446,000 | 24,905,000 | 60,220,000 |
| Mar 2026 | 0 | — | -20,436,000 | -19,625,000 | 183,622,000 | 61,697,000 | 63,989,000 |
| Dec 2025 | 1,292,000 | — | -15,883,000 | -50,042,000 | 113,506,000 | 21,824,000 | 62,067,000 |
| Sep 2025 | 1,090,000 | — | -19,237,000 | -18,061,000 | 161,550,000 | 24,155,000 | 62,518,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-67,948,000
Investing CF
$-27,629,000
Financing CF
$85,803,000
CapEx
$-317,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-7.42
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-422,387,000
Inventory
—
Receivables
$0
ST Investments
$90,131,000
EBIT TTM
$-75,666,000
Pretax Income TTM
$-105,805,000
Interest Exp TTM
—
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,382,000
EBITDA
$-74,326,000
Free Cash Flow
$-41,390,124
Enterprise Value
$130,538,168
Total Cash
$115,036,000
Total Debt
$42,213,000
Shares Out
14,725,646
Trailing EPS
$-9.88
Book Value
$7.02
ROE
-97.7%
ROA
-28.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,392,000 | -87,342,000 | -117,260,000 | 113,506,000 | 62,067,000 | 51,439,000 | -78,561,000 |
| Dec 2024 | 2,271,000 | -91,910,000 | -83,581,000 | 226,240,000 | 65,825,000 | 160,415,000 | -60,074,000 |
| Dec 2023 | 0 | -84,534,000 | -81,172,000 | 221,663,000 | 51,752,000 | 169,911,000 | -67,283,000 |
| Dec 2022 | 0 | -58,998,000 | -58,032,000 | 73,742,000 | 172,773,000 | -99,031,000 | -53,645,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.46
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $9.51 · call volume: 28 · put volume: 0
Expected Move to 2027-01-15:
±$4.64
(48.79%) —
implied range
$4.87 –
$14.15
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DERM | Journey Medical Corp | $142.90M | $6.43 | — |
| SPRB | SPRUCE BIOSCIENCES, INC. | $136.54M | $47.51 | — |
| RNA | Atrium Therapeutics, Inc. | $144.03M | $8.42 | — |
| MENS | Jyong Biotech Ltd. | $146.24M | $1.97 | — |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $133.84M | $6.92 | — |
News headlines (Yahoo Finance, 1h cache)
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-09-11 20:05 · Yahoo
Korro to Participate in Upcoming Investor Conferences
2026-08-27 11:00 · Yahoo
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-06 11:00 · Yahoo
Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?
2026-07-08 16:00 · Yahoo
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
2026-06-19 12:06 · Yahoo
One Korro Bio Insider Raised Stake By 19% In Previous Year
2026-06-11 11:38 · Yahoo
Korro to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-27 11:00 · Yahoo
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
2026-05-19 11:00 · Yahoo
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock
2026-04-28 16:00 · Yahoo
Junevity Partners with Sunrise BioVentures as Advisors to Accelerate siRNA Therapeutic Development
2026-06-10 12:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.